Nish Patel1, Christine Ju2, Conrad Macon3, Udho Thadani4, Phillip J Schulte2, Adrian F Hernandez2, Deepak L Bhatt5, Javed Butler6, Clyde W Yancy7, Gregg C Fonarow8. 1. Division of Cardiology, University of Miami Miller School of Medicine, Miami, Florida; Division of Cardiology, University of Oklahoma Health Sciences Center and VA Medical Center, Oklahoma City, Oklahoma. 2. Duke Clinical Research Institute, Durham, North Carolina. 3. Division of Cardiology, University of Miami Miller School of Medicine, Miami, Florida. 4. Division of Cardiology, University of Oklahoma Health Sciences Center and VA Medical Center, Oklahoma City, Oklahoma. 5. Division of Cardiology, Brigham and Woman's Hospital Heart & Vascular Center and Harvard Medical School, Boston, Massachusetts. 6. Division of Cardiology, Stony Brook School of Medicine, Stony Brook, New York. 7. Division of Cardiology, Northwestern Feinberg School of Medicine, Chicago, Illinois. 8. Division of Cardiology, Ronald Reagan-UCLA Medical Center, Los Angeles, California. Electronic address: gfonarow@mednet.ucla.edu.
Abstract
OBJECTIVES: The aim of this study was to assess temporal trends and factors associated with digoxin use at discharge among patients admitted with heart failure (HF). BACKGROUND: Digoxin has class IIa recommendations for treating HF with reduced ejection fraction (HFrEF) in the United States. Digoxin use, temporal trends, and clinical characteristics of HF patients in current clinical practice in the United States have not been well studied. METHODS: An observational analysis of 255,901 patients hospitalized with HF (117,761 with HFrEF and 138,140 with preserved EF [HFpEF]) from 398 hospitals participating in the Get With The Guidelines-HF registry between January 2005 and June 2014 was conducted to assess the temporal trends and factors associated with digoxin use. RESULTS: Among 117,761 HFrEF patients, only 19.7% received digoxin at discharge. Digoxin prescriptions decreased from 33.1% in 2005 to 10.7% in 2014 (ptrend < 0.0001). Factors associated with digoxin use in HFrEF included atrial fibrillation (AF) (odds ratio [OR]: 2.14; 95% confidence intervals [CI]: 2.02 to 2.28), history of implantable cardioverter defibrillator use (OR: 1.39; 95% CI: 1.32 to 1.46), chronic obstructive pulmonary disease (OR: 1.13, 95% CI: 1.08 to 1.18), diabetes mellitus (OR: 1.10, 95% CI: 1.06 to 1.14), younger age (OR: 0.96, 95% CI: 0.95 to 0.97), lower blood pressure (OR: 0.96, 95% CI: 0.96 to 0.97), and having no history of renal insufficiency (OR: 0.91, 95% CI: 0.85 to 0.97). Use of digoxin in patients with HFpEF (n = 138,140) without AF was 9.8% in 2005, which decreased to 2.2% in 2014 (ptrend < 0.0001). CONCLUSIONS: One in 5 HFrEF patients received digoxin at discharge, with a significant downward temporal trend in use over the study period. Use of digoxin in HFpEF patients without AF was very low and decreased over the study period.
OBJECTIVES: The aim of this study was to assess temporal trends and factors associated with digoxin use at discharge among patients admitted with heart failure (HF). BACKGROUND:Digoxin has class IIa recommendations for treating HF with reduced ejection fraction (HFrEF) in the United States. Digoxin use, temporal trends, and clinical characteristics of HF patients in current clinical practice in the United States have not been well studied. METHODS: An observational analysis of 255,901 patients hospitalized with HF (117,761 with HFrEF and 138,140 with preserved EF [HFpEF]) from 398 hospitals participating in the Get With The Guidelines-HF registry between January 2005 and June 2014 was conducted to assess the temporal trends and factors associated with digoxin use. RESULTS: Among 117,761 HFrEF patients, only 19.7% received digoxin at discharge. Digoxin prescriptions decreased from 33.1% in 2005 to 10.7% in 2014 (ptrend < 0.0001). Factors associated with digoxin use in HFrEF included atrial fibrillation (AF) (odds ratio [OR]: 2.14; 95% confidence intervals [CI]: 2.02 to 2.28), history of implantable cardioverter defibrillator use (OR: 1.39; 95% CI: 1.32 to 1.46), chronic obstructive pulmonary disease (OR: 1.13, 95% CI: 1.08 to 1.18), diabetes mellitus (OR: 1.10, 95% CI: 1.06 to 1.14), younger age (OR: 0.96, 95% CI: 0.95 to 0.97), lower blood pressure (OR: 0.96, 95% CI: 0.96 to 0.97), and having no history of renal insufficiency (OR: 0.91, 95% CI: 0.85 to 0.97). Use of digoxin in patients with HFpEF (n = 138,140) without AF was 9.8% in 2005, which decreased to 2.2% in 2014 (ptrend < 0.0001). CONCLUSIONS: One in 5 HFrEF patients received digoxin at discharge, with a significant downward temporal trend in use over the study period. Use of digoxin in HFpEF patients without AF was very low and decreased over the study period.
Authors: Andrew P Ambrosy; Ankeet S Bhatt; Amanda L Stebbins; Lisa M Wruck; Marat Fudim; Stephen J Greene; William E Kraus; Christopher M O'Connor; Ileana L Piña; David J Whellan; Robert J Mentz Journal: Am Heart J Date: 2018-02-11 Impact factor: 4.749
Authors: Nancy Luo; Haolin Xu; Hani Jneid; Gregg C Fonarow; Renato D Lopes; Jonathan P Piccini; Anne B Curtis; Andrea M Russo; William R Lewis; Roland A Matsouaka; Christopher B Granger; Robert J Mentz; Sana M Al-Khatib Journal: Circ Heart Fail Date: 2018-10 Impact factor: 8.790
Authors: Udo Bavendiek; Dominik Berliner; Lukas Aguirre Dávila; Johannes Schwab; Lars Maier; Sebastian A Philipp; Andreas Rieth; Ralf Westenfeld; Christopher Piorkowski; Kristina Weber; Anja Hänselmann; Maximiliane Oldhafer; Sven Schallhorn; Heiko von der Leyen; Christoph Schröder; Christian Veltmann; Stefan Störk; Michael Böhm; Armin Koch; Johann Bauersachs Journal: Eur J Heart Fail Date: 2019-03-20 Impact factor: 15.534
Authors: Lorenzo Gigli; Pietro Ameri; Gianmarco Secco; Gabriele De Blasi; Roberta Miceli; Alessandra Lorenzoni; Francesco Torre; Francesco Chiarella; Claudio Brunelli; Marco Canepa Journal: World J Cardiol Date: 2016-11-26